Skip to main content
Figure 3 | Molecular Cancer

Figure 3

From: Melanoma-associated Chondroitin Sulfate Proteoglycan (MCSP)-targeted delivery of soluble TRAIL potently inhibits melanoma outgrowth in vitro and in vivo

Figure 3

Anti-MCSP:TRAIL triggers dephosphorylation of cellular proteins. A375M cells were treated with anti-MCSP:TRAIL, anti-MCSP mAb 9.2.27, rhTRAIL or left untreated for 1 h. Whole cell lysates were analyzed for phosphorylation of 48 cellular kinases. A Phosphorylation of 28 kinases in untreated cells (left panel) or anti-MCSP:TRAIL-treated cells (right panel) are depicted. Images are representative of three independent experiments. B, C, D Changes in the phosphorylation of 21 kinases after treatment with B anti-MCSP:TRAIL, C anti-MCSP mAb 9.2.27 or D rhTRAIL are expressed as a percentage of the phosphorylation measured in untreated cells. E A375M cells were treated with anti-MCSP:TRAIL for 0, 30, 60 or 240 min. Whole cell lysates were analyzed for phosphorylation of 48 cellular kinases. Changes in phosphorylation of the different kinase groups as indicated in panel B are depicted. *, p < 0.05; **, p < 0.001; ***, p < 0.0001.

Back to article page